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Glucocorticoids suppress inﬂammation via the
upregulation of negative regulator IRAK-M
Masanori Miyata1,*, Ji-Yun Lee1,*, Seiko Susuki-Miyata1, Wenzhuo Y. Wang1,2, Haidong Xu1, Hirofumi Kai3,
Koichi S. Kobayashi4, Richard A. Flavell5 & Jian-Dong Li1
Glucocorticoids are among the most commonly used anti-inﬂammatory agents. Despite the
enormous efforts in elucidating the glucocorticoid-mediated anti-inﬂammatory actions, how
glucocorticoids tightly control overactive inﬂammatory response is not fully understood. Here
we show that glucocorticoids suppress bacteria-induced inﬂammation by enhancing IRAK-M,
a central negative regulator of Toll-like receptor signalling. The ability of glucocorticoids
to suppress pulmonary inﬂammation induced by non-typeable Haemophilus inﬂuenzae is
signiﬁcantly attenuated in IRAK-M-deﬁcient mice. Glucocorticoids improve the survival rate
after a lethal non-typeable Haemophilus inﬂuenzae infection in wild-type mice, but not in
IRAK-M-deﬁcient mice. Moreover, we show that glucocorticoids and non-typeable
Haemophilus inﬂuenzae synergistically upregulate IRAK-M expression via mutually and
synergistically enhancing p65 and glucocorticoid receptor binding to the IRAK-M promoter.
Together, our studies unveil a mechanism by which glucocorticoids tightly control the
inﬂammatory response and host defense via the induction of IRAK-M and may lead to further
development of anti-inﬂammatory therapeutic strategies.
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G
lucocorticoids (GCs) are the most widely used and most
effective treatment to control inﬂammatory diseases1–3.
GCs are known to exert their anti-inﬂammatory effects
by binding to glucocorticoid receptors (GRs), leading to the
suppression of proinﬂammatory regulators such as nuclear
factor-kB (NF-kB) or activator protein 1 (AP-1) (refs 4,5).
Several mechanisms of action of GR have been reported in the
past6. First, GR binds to p65 and AP-1 to prevent downstream
transcription (tethering). Second, GR binds to the glucocorticoid
response element (GRE) to initiate the transcription of
anti-inﬂammatory genes (transactivation). Third, negative GRE
has been shown to suppress proinﬂammatory cytokines
(transrepression)7,8.
The innate immune and inﬂammatory response is activated
by pattern recognition receptors, including Toll-like receptors
(TLRs), on recognition of pathogen-associated molecular
patterns9. Pattern recognition receptors activate a number of
downstream molecules such as tumour necrosis factor (TNF)
receptor-associated factor 6 (TRAF6), NF-kB essential modulator,
inhibitor of NF-kB (IkB) kinase b (IKKb) and NF-kB to produce
proinﬂammatory cytokines9. Myeloid differentiation factor 88
(MyD88) is a critical downstream adaptor molecule of all TLRs,
except TLR3, and interleukin-1 (IL-1) receptor (IL-1R) family
(IL-1a, IL-1b, IL-18 and IL-33) signalling by recruiting IL-1R-
associated kinase 1 (IRAK1), IRAK4 and TRAF6 (refs 9,10).
The studies of MyD88-deﬁcient mice and humans suggest
that MyD88 plays a pivotal role in initiating inﬂammatory
responses11,12.
Negative feedback regulators of inﬂammation have been
recently suggested to play essential roles in tightly controlling
inﬂammatory responses to preserve homeostasis10. IRAK-M (also
known as IRAK3) is one of the most critical negative feedback
regulators of the TLR/IL-1R family signalling via the inhibition of
MyD88 and IRAK1/4 activation13–16. IRAK-M is a member of
the IRAK family and is composed of three conserved domains.
However, it does not have any kinase activity due to the lack of a
key aspartate in its kinase domain. Thus, IRAK-M has been
thought to be a competitor for IRAK1 in associating with
MyD88 and TRAF6 (ref. 13). Indeed, IRAK-M-deﬁcient mice
exhibited increased inﬂammatory response in several models15–19.
IRAK-M expression was initially characterized in monocytes/
macrophages16,20,21. Recent studies also demonstrate the
expression of IRAK-M in airway epithelial cells20,22. Induction of
IRAK-M expression by a number of inﬂammatory stimuli has been
shown to suppress inﬂammation in a negative feedback manner in
multiple cell types including macrophages and epithelial cells18,19.
However, it is unclear if GCs suppress overactive inﬂammatory
responses via induction of negative feedback regulators such as
IRAK-M.
In the present study, we show that GCs synergistically
enhances IRAK-M expression induced by non-typeable
Haemophilus inﬂuenzae (NTHi), not only in airway epithelial
cells, but also in macrophages. We found that the overexpression
of IRAK-M suppresses, whereas IRAK-M depletion enhances, the
NTHi-induced expression of proinﬂammatory mediators. We
further found that IRAK-M-deﬁciency attenuates the ability of
dexamethasone (DEX) to suppress pulmonary inﬂammation
induced by NTHi infection. Lethal NTHi infection-caused
mortality was improved by DEX treatment in wild type (WT),
but not in IRAK-M-deﬁcient mice. Together our results suggest
that the induction of IRAK-M by GCs may be critical to suppress
overactive pulmonary inﬂammatory response in vitro and in vivo.
These results thus identiﬁed IRAK-M as a novel functional target
of GCs.
Results
GCs synergistically enhance NTHi-induced IRAK-M expression.
We sought to determine if GCs regulate the expression of
IRAK-M induced by NTHi. Because airway epithelial cells are the
front line of defense through initiating inﬂammatory response, we
ﬁrst examined the effect of GCs on NTHi-induced expression in
human respiratory epithelial cells BEAS-2B and A549. DEX
synergistically enhanced the NTHi-induced IRAK-M expression
at the mRNA level in BEAS-2B and A549 in a dose- and time-
dependent manner (Fig. 1a,b and Supplementary Fig. 1a,b).
Immunoblot analysis revealed that DEX also synergistically
enhanced NTHi-induced IRAK-M expression at the protein level
(Fig. 1c,d). Moreover, DEX-mediated synergistic enhancement of
NTHi-induced IRAK-M expression is also conﬁrmed in primary
normal human bronchial epithelial cells (Fig. 1e). We also
examined the effect of GCs on IRAK-M expression in macro-
phages due to their important role in innate immune responses
against bacteria23,24. As shown in Fig. 1f, the induction of
IRAK-M by NTHi and DEX was also observed in primary human
monocyte-derived macrophages. Under the same experimental
condition, NTHi-induced IL-6 expression was suppressed by
DEX (Supplementary Fig. 2). Consistent with these results, DEX
also synergistically enhanced the NTHi-induced IRAK-M
expression in primary alveolar macrophages of mice (Fig. 1g).
Moreover, DEX also synergistically enhanced the NTHi-induced
IRAK-M expression at both mRNA and protein levels in lung
tissue of mice, as assessed by performing qPCR and
immunostaining analyses (Fig. 1h–j). To further determine
which cells express IRAK-M in the lung of mice treated with
NTHi and DEX, we next performed immunoﬂuorescence double
staining using anti-IRAK-M with anti-E-cadherin or anti-F4/80
antibodies, the marker of epithelial cells and macrophages,
respectively. As shown in Fig. 1k, NTHi and DEX markedly
induced the expression of IRAK-M in both epithelial cells and
macrophages. Of note, IRAK-M-speciﬁc staining was completely
abolished by an IRAK-M-speciﬁc blocking peptide (Fig. 1k).
Figure 1 | DEX synergistically enhances the NTHi-induced IRAK-M expression in vitro and in vivo. (a) IRAK-M mRNA expression in human bronchial
epithelial BEAS-2B cells treated with DEX (0.01, 0.1, 1, 10, 100 or 1,000nM) for 1 h, followed by the stimulation of NTHi for 5 h. (b) IRAK-M mRNA
expression in human lung epithelial A549 cells stimulated with DEX (100 nM) for 1 h, followed by NTHi for indicated time. (c) A549 cells were treated with
DEX (100 nM) for 1 h, followed by NTHi for 12 h. IRAK-M protein was detected by anti-IRAK-M antibody. (d) IRAK-M protein expression was quantiﬁed
from three independent experiments. (e) IRAK-M mRNA expression in primary NHBE cells treated with DEX (10, 100 or 1,000nM) for 1 h and subjected to
NTHi stimulation for 5 h. (f) Human peripheral blood CD14þ monocytes were differentiated to macrophages by culturing them with granulocyte–
macrophage colony-stimulating factor for 7 days. IRAK-M mRNA was determined after the macrophages were treated with DEX (100 nM) for 1 h, followed
by stimulation of NTHi for 5 h. (g) Mice were stimulated with DEX (1mg kg 1, intraperitoneally) for 2 h and intratracheally inoculated with NTHi
(1 107 c.f.u.) for 24 h. The mRNA expression in alveolar macrophages was assessed by qPCR. (h) The IRAK-M mRNA expression in lung was assessed by
qPCR. (i) Immunostaining of mouse lung with control IgG or anti-IRAK-M antibody by LSAB (Labelled Streptavidin Biotin) staining system (Scale bar,
50mm; magniﬁcation, 400). (j) Treatment-blind observers scored the IRAK-M expression from the histology results. (k) The lung sections were stained
by using indicated antibodies. The arrows and arrowheads indicate the epithelial cells and macrophages merged with IRAK-M expression, respectively.
(Scale bar, 50mm; magniﬁcation, 400. Data in a,b,d-h, n¼ 3; j, n¼ 6) are mean±s.d. *Po0.05; t-test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7062
2 NATURE COMMUNICATIONS | 6:6062 | DOI: 10.1038/ncomms7062 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Taken together, our data suggest that DEX synergistically
enhances NTHi-induced IRAK-M expression at both mRNA
and protein levels in vitro and in vivo.
IRAK-M negatively regulates the NTHi-induced inﬂammation.
To determine the role of the induction of IRAK-M expression in
the NTHi-induced inﬂammatory responses, we established stable
BEAS-2B cells expressing IRAK-M (IRAK-M-stable cells; Fig. 2a).
As shown in Fig. 2b, the NTHi-induced expression of TNF-a,
IL-1b, IL-6, CXCL10 and CCL5 was signiﬁcantly inhibited in
IRAK-M-stable cells as compared with mock cells. Next we
sought to conﬁrm the role of endogenous IRAK-M expression in
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NTHi-induced expression of proinﬂammatory mediators by
depleting IRAK-M using short interfering RNA (siRNA).
Immunoblot analysis using two different anti-IRAK-M antibodies
revealed that the siRNA depletion of IRAK-M speciﬁcally reduced
IRAK-M expression (Fig. 2c). IRAK-M depletion markedly
enhanced NTHi-induced expression of TNF-a, IL-1b, IL-6,
CXCL10 and CCL5 (Fig. 2d). Moreover, the ability of DEX to
suppress these proinﬂammatory mediators was also signiﬁcantly
attenuated in IRAK-M-depleted cells (Fig. 2e). These data thus
provide direct evidence for the role of the induction of IRAK-M
expression in NTHi-induced inﬂammatory responses in the
presence of DEX.
GCs suppress inﬂammation and improve survival via IRAK-M.
To determine if DEX suppresses NTHi-induced inﬂammatory
response via the induction of IRAK-M expression, we compared
the inhibitory effect of DEX on NTHi-induced innate inﬂam-
matory response in WT (Irak-mþ /þ ) with IRAK-M-deﬁcient
(Irak-m / ) mice. We observed that DEX markedly suppressed
the NTHi-induced mRNA expression of key proinﬂammatory
mediators including TNF-a, IL-1b, IL-6, MIP2, CXCL5/LIX,
CXCL10 and CCL5, at the mRNA level, in Irak-mþ /þ but not in
Irak-m / mice (Fig. 3a). Enzyme-linked immunosorbent assay
analysis conﬁrmed that DEX failed to markedly suppress the
NTHi-induced expression of these proinﬂammatory mediators at
the protein level in the bronchoalveolar lavage (BAL) ﬂuid of
Irak-m / mice as compared with Irak-mþ /þ mice (Fig. 3b).
Consistent with these results, similar results were also observed in
mouse alveolar macrophages (Fig. 3c). Moreover, histopatholo-
gical analysis of the lung of NTHi-infected mice showed that
DEX inhibited NTHi-induced leukocyte inﬁltration in the
peribroncheal and interstitial area and also inhibited alveolar wall
injury by the inﬂammatory process in Irak-mþ /þ but not in
Irak-m / mice (Fig. 4a,b). Similarly, DEX also suppressed
NTHi-induced leukocytes inﬁltration in BAL ﬂuid of Irak-mþ /þ
mice but not of Irak-m / mice (Fig. 4c). Because an innate
inﬂammatory response initiated by pulmonary epithelial cells is
critical for bacterial clearance, we further evaluated the effects of
DEX on bacterial clearance in the lungs of Irak-m / mice
compared with Irak-mþ /þ mice. DEX treatment increased the
colony-formation unit (c.f.u.) of NTHi in the lung of Irak-mþ /þ
mice, but not in the lung of Irak-m / mice (Fig. 4d).
Consistent with the result of bacterial clearance, DEX also
inhibited the NTHi-induced expression of mouse b-defensin 4,
an orthologue of human BD2, in Irak-mþ /þ mice, but not in
Irak-m / mice (Fig. 4e). Because overactive inﬂammatory
responses contribute signiﬁcantly to the increased morbidity and
mortality in patients with NTHi infections25,26, we next evaluated
the contribution of IRAK-M in mortality induced by NTHi by
infecting mice with a lethal dose of NTHi (5 108 c.f.u.) and
monitoring survival rate for 7 days. As shown in Fig. 4f,
we observed B50% mortality in Irak-mþ /þ mice 7 days after
infection. We found no statistically signiﬁcant difference in
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Figure 2 | IRAK-M suppresses the NTHi-induced proinﬂammatory mediator expression. (a) The proteins from BEAS-2B cells stably overexpressing
IRAK-M and its control pcDNA3.1 (Mock) cells were detected by immunoblot with indicated antibodies. (b) The mRNA expression was detected by qPCR
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protein expression was detected by immunoblot with anti-IRAK-M antibodies (SC, Santa Cruz Biotechnology sc-100389; PS, ProSci #2355).
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survival rate between DEX-untreated Irak-mþ /þ and Irak-m /
mice (P¼ 0.362). Notably, the survival rate was signiﬁcantly
improved by DEX in Irak-mþ /þ but not in Irak-m / mice
(Fig. 4f). Collectively, our data suggest that DEX suppressed
bacteria-induced innate inﬂammatory response and improved
survival via the upregulation of IRAK-M expression.
IKKb and GR mediate synergistic induction of IRAK-M.
Having shown that GCs suppress NTHi-induced inﬂammatory
response via the induction of IRAK-M, the mechanism under-
lying the regulation of IRAK-M expression still remains
unknown. Because NTHi is recognized by TLR2 (refs 27–29), we
sought to ﬁrst evaluate the generalizability of our ﬁndings by
determining if DEX also enhances the induction of IRAK-M
expression by TLR-dependent and -independent inﬂammatory
stimuli. GCs enhanced upregulation of IRAK-M by TNFa, IL-1b
and Pam3CSK4 in lung epithelial cells (Fig. 5a). Because all of
these stimuli that induce IRAK-M, including NTHi, are known to
induce inﬂammatory response via IKKb27–29, we thus examined
if DEX synergistically enhances upregulation of IRAK-M induced
by activating IKKb signalling through the overexpression of a
constitutively active form of IKKb (IKKb CA). DEX indeed
synergistically enhanced the induction of IRAK-M by the direct
activation of IKKb signalling (Fig. 5b). We further determined
if IKKb mediates the synergistic upregulation of IRAK-M by
DEX and NTHi. Inhibition of IKKb using speciﬁc inhibitor
signiﬁcantly suppressed the synergistic upregulation of IRAK-M
expression at both mRNA and protein levels by DEX and NTHi
(Fig. 5c,d), suggesting the requirement of IKKb signalling in
mediating the synergistic induction of IRAK-M.
Because GR is crucial for GC-mediated biological effects5,6,
we next assessed the role of GR using RU486 (mifepristone),
a GR antagonist. RU486 signiﬁcantly inhibited the synergistic
upregulation of IRAK-M expression at both mRNA and protein
levels by DEX and NTHi in BEAS-2B and A549 cells (Fig. 5e,f
and Supplementary Fig. 3a). Moreover, GR depletion using
siRNA also markedly inhibited the synergistic upregulation of
IRAK-M by DEX and NTHi (Fig. 5g and Supplementary Fig. 3b),
indicating that GR mediates synergistic induction of IRAK-M.
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Figure 3 | DEX suppresses the NTHi-induced proinﬂammatory mediator expression in Irak-mþ /þ but not in Irak-m / mice. WTand IRAK-M-deﬁcient
mice were inoculated with DEX (1mg kg 1, intraperitoneally) for 2 h, followed by intratracheal inoculation with NTHi (1 107 c.f.u. per lung) for 24 h.
(a) The mRNA expression in the mouse lung tissue was analysed by qPCR. (b) The protein level of proinﬂammatory mediators in BAL ﬂuid was determined
by enzyme-linked immunosorbent assay. (c) The mRNA expression in alveolar macrophages was analysed by qPCR. Data in a,c, n¼ 3; b, n¼9 are
mean±s.d. *Po0.05, NS, non-signiﬁcant; t-test.
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GR is known to regulate gene expression by inﬂuencing
transcription or mRNA stability30,31. Interestingly, the mRNA
stability of IRAK-M remained largely unchanged by NTHi or
DEX (Supplementary Fig. 4). Consistent with this result,
actinomycin D, a transcriptional inhibitor, abrogated the
synergistic induction of IRAK-M protein expression induced by
DEX and NTHi (Fig. 5h). These data suggest that DEX and NTHi
are unable to induce IRAK-M expression in the absence of the
on-going transcription.
We sought to further elucidate the molecular mechanism
underlying the synergistic induction of IRAK-M by DEX and
NTHi. DEX is known to exert its transcriptional activity via the
induction of the ligand-dependent dimerization of GR and the
subsequent binding of the dimerized GR to GRE in the gene
regulatory region of the driven genes4–6. We thus ﬁrst determined
if the ligand-induced binding of GR dimer to the GRE in the
promoter region of IRAK-M is involved in the synergistic
induction of IRAK-M transcription by using a non-steroidal
GR-monomer-favouring compound, compound A (CpdA).
Unlike DEX, CpdA exhibits no effect on GRE-driven gene
transcription32. We found that CpdA failed to enhance NTHi-
induced expression of IRAK-M (Fig. 5i). In contrast, it still
signiﬁcantly inhibited the NTHi-induced NF-kB activity (Fig. 5j).
These data thus suggest that the binding of dimerized GR to GRE
is required for the synergistic induction of IRAK-M transcription
by DEX and NTHi.
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(a) Haematoxylin and eosin (H&E) staining of lung tissues from mice (Scale bar, 200mm, magniﬁcation,  100 in large frame; Scale bar 50mm,
magniﬁcation, 400 in inserted frame). (b) Blinded histopathologic scoring of lung inﬂammation was performed on H&E-stained lung sections in a
grade 0–3. (c) The number of PMN cells from BAL ﬂuid was counted using a haemocytometer under the microscope. (d) Bacterial loads (c.f.u.) in lung
homogenates. (e) The mRNA expression of mBD4 in lung was measured by qPCR (f) WT and IRAK-M-deﬁcient mice were inoculated with DEX
(1mg kg 1, intraperitoneally) for 2 h, followed by intratracheal inoculation with lethal dose of NTHi (5 108 c.f.u. per lung) for 7 days. Survival rate
was monitored for indicated days. P values were determined by Kaplan–Meier survival analysis with GraphPad Prism 5.0. Data in b¼8; c,e, n¼ 3; d¼ 10,
f¼ 20 are mean±s.d. *Po0.05, NS, non-signiﬁcant; t-test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7062
6 NATURE COMMUNICATIONS | 6:6062 | DOI: 10.1038/ncomms7062 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
GR and p65 synergistically bind to IRAK-M promoter. We next
sought to deﬁne the cis-acting DNA elements critical for the
synergistic induction of IRAK-M. We constructed a series of
deletion mutants in the upstream region of IRAK-M promoter,
inserted them to a pGL3 basic vector and measured their
luciferase activity. As shown in Fig. 6a, the key cis-acting elements
critical for mediating the synergistic induction of IRAK-M tran-
scription resided within the promoter region from  500 to þ 71
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Figure 5 | DEX synergistically enhances the NTHi-induced IRAK-M expression via IKKb and GR. (a) Immunoblot shows that IRAK-M protein expression in
BEAS-2B cells treated with DEX (100 nM) and NTHi, TNF-a (10 ngml 1), IL-1b (1 ngml 1) or Pam3CSK4 (1mgml 1). (b) IRAK-M mRNA expression
assessed by qPCR in A549 cells transfected with constitutive active form of IKKb (IKKb CA) with DEX (100nM). (c–f), IRAK-M expression in BEAS-2B
cells treated with DEX (100 nM) and NTHi, IKKb inhibitor (1 mM) (c,d) or RU486 (1mM; e,f). (g) Immunoblot shows IRAK-M protein expression in BEAS-2B
cells transfected with siRNA GR. (h) BEAS-2B cells were treated with NTHi, DEX (100 nM) and actinomycin D, ActD (5mgml 1), followed by immunoblot.
(i) The expression of IRAK-M mRNA in BEAS-2B cells treated with DEX (100nM) and Compound A, CpdA (1 or 10mM) followed by NTHi stimulation
for 5 h. (j) Relative luciferase activity (RLA) of NF-kB is measured by luciferase assay. BEAS-2B cells transfected with NF-kB luciferase plasmid were
treated with CpdA and NTHi. Data (b,c,e,i,j, n¼ 3) are mean±s.d. *Po0.05, NS; t-test.
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base pair (bp). Further in silico sequence analysis revealed the
existence of three putative NF-kB-binding sites (kB site) and one
GRE in the IRAK-M promoter region from  300 to þ 71 bp
(Supplementary Fig. 5). Interestingly, mutation of this GRE and
these three kB sites markedly inhibited the synergistic activation
of IRAK-M promoter by DEX and NTHi (Fig. 6b), thereby fur-
ther demonstrating the requirement of NF-kB and GR. Since p65
is a key subunit of NF-kB33, we next determined if p65 is
critically involved in this synergistic induction of IRAK-M. We
observed no synergistic induction of IRAK-M in p65-deﬁcient
mouse embryonic ﬁbroblasts (MEFs) treated with NTHi and
DEX as compared with WT MEFs, and the reconstitution of
p65-deﬁcient MEFs with WT p65 plasmid restored their
responsiveness to NTHi and DEX (Fig. 6c). Consistent with
these results, p65 knockdown by siRNA inhibited the synergistic
induction of IRAK-M expression at the protein level in BEAS-2B
cells (Fig. 6d and Supplementary Fig. 6a) and DEX also
synergistically enhanced IRAK-M expression induced by
expressing WT p65 in BEAS-2B cells (Supplementary Fig. 6b).
Taken together, our data suggest that both p65 and GR are
required for mediating the synergistic induction of IRAK-M
transcription by DEX and NTHi.
We next determined if DEX synergizes with NTHi to induce
IRAK-M transcription via synergistically inducing the binding of
p65 and GR to IRAK-M promoter region ( 300 bp to þ 71 bp)
containing three kB sites and GRE. Quantitative analyses using
chromatin immunoprecipitation (ChIP) assays revealed that DEX
and NTHi synergistically enhanced the binding of both p65 and
GR to IRAK-M promoter (Fig. 6e,f). In addition, Re-ChIP assay34
revealed that DEX and NTHi induced the interaction of p65
with GR in the context of chromatin (Fig. 6g). Moreover, the
synergistic induction of the binding of p65 and GR to IRAK-M
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Figure 6 | DEX and NTHi synergistically induce IRAK-M transcription via inducing the binding of p65 and GR to IRAK-M promoter. (a–c) Relative
luciferase activity (RLA) was measured after the transfection of IRAK-M promoter in pGL3 basic vector and treated with DEX (100 nM) and NTHi in
BEAS-2B cells (a,b). (c) MEF cells were transfected with IRAK-M-luc ( 500bp), followed by DEX (1mM) and NTHi stimulation. (d) Immunoblot
shows IRAK-M protein expression in BEAS-2B cells transfected with siRNA p65. (e,f) ChIP assay in BEAS-2B cells treated with DEX and NTHi for 1 h.
IRAK-M promoter regions from  38 to þ 39 bp for GRE, from  231 to  99 bp for kB site were ampliﬁed by qPCR. (g) Re-ChIP assay (detailed in
Methods). PCR products were detected in agarose gel. (h,i) ChIP assay in BEAS-2B cells treated with IKKb inhibitor (1 mM), RU486 (1 mM), DEX (100 nM)
and NTHi. Data (a–c, n¼ 3; e,f, n¼ 2) are mean±s.d. *Po0.05; t-test.
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promoter induced by NTHi and DEX was signiﬁcantly inhibited
by RU486 and IKKb inhibitor, respectively (Fig. 6h,i). Together
these data suggest that DEX synergizes with NTHi to induce the
binding of both GR and p65 to IRAK-M promoter, which, in
turn, leads to the induction of IRAK-M transcription in a
synergistic manner (Fig. 7).
Discussion
On infection, an innate inﬂammatory response can be activated
through a TLR. The adaptor proteins IRAK1 and IRAK4
(IRAK1/4) and MyD88 mediate all TLR signalling, except
TLR3, in triggering inﬂammation. It has been demonstrated that
MyD88 and IRAK1/4 are critical in activating an inﬂammatory
response in mice12,35 as well as in humans11,36. Since GCs have a
potent anti-inﬂammatory effect for multiple usages in a clinical
setting, we hypothesized that GCs could target central bottleneck
proteins such as MyD88 or IRAK1/4 to tightly regulate
inﬂammatory responses. Here we show that GCs synergistically
enhance bacteria-induced IRAK-M, a critical negative regulator
of IRAK1/4, in vitro and in vivo. We found that NTHi and GCs
cooperatively induced recruitment of p65 and GR to the IRAK-M
promoter. In addition, the inhibitory effect of DEX on NTHi-
induced inﬂammatory response is signiﬁcantly attenuated in mice
lacking IRAK-M. Thus, we propose that IRAK-M is a novel
functional target of GCs for suppression of bacteria-induced
inﬂammation.
In the present study, we provided experimental evidence for a
novel anti-inﬂammatory mechanisms by which GCs suppress
inﬂammation via the cooperative upregulation of IRAK-M by the
GR and NF-kB. This ﬁnding may be of particular signiﬁcance
as it contradicts a widespread assumption that GCs exert their
anti-inﬂammatory effects principally by antagonizing NF-kB
activity4,5. If extended to other models of inﬂammatory diseases,
our study may have signiﬁcant translational implications for
design of novel anti-inﬂammatory agents. Previous studies have
predominantly focused on understanding the GC-mediated anti-
inﬂammatory actions through the inhibition of positive regulators
such as NF-kB and AP-1. Although it has been shown that GCs
suppress inﬂammation by targeting more distal regulators such as
IkBa or MKP-1 (refs 37–39), the role of GCs in regulating more
proximal and central regulators of inﬂammation, such as the key
bottleneck proteins MyD88 and IRAK1/4, remains unknown.
Recently, systematic approaches revealed that MyD88 is a non-
redundant core element40,41. Owing to GCs’ prominence among
anti-inﬂammatory agents, it is logical that GCs may target
MyD88-IRAK1/4 to tightly control inﬂammation. Thus, our
study provides novel insight into the tight regulation of MyD88
and IRAK1/4 via modulating the endogenous inhibitor IRAK-M
by GCs.
GR has been shown to suppress inﬂammatory responses via the
inhibition of p65-induced transcription4,37,42. A recent genome-
wide study revealed that GR and p65 mutually enhance their
binding to a speciﬁc promoter43. Thus, the regulation of p65- and
GR-associated transcription is likely gene speciﬁc. Despite
previous studies showing that the expression of IRAK-M is
induced by inﬂammatory stimuli in macrophages22,44–47 and in
osteoblasts48, the precise molecular mechanism of IRAK-M
regulation at the transcriptional level remains to be understood.
We demonstrated that the co-treatment of cells with both NTHi
and GCs leads to the synergistic binding of p65 and GR to the
IRAK-M promoter. Interestingly, NTHi- and GR-induced
binding of p65 to the IRAK-M promoter is inhibited by the GR
antagonist, RU486 (Fig. 6h). Conversely, we also observed a
decrease in GR binding in the presence of IKKb inhibitor
(Fig. 6i). Consistent with previous studies, our data suggest that
both p65 and GR synergize with each other to bind to the
IRAK-M promoter. These data suggest a novel regulatory
mechanism for IRAK-M promoter activity. Future studies
investigating how the p65-GR complex activates IRAK-M
transcription may lead to a better understanding of the
elaborate interplay between bacteria and GCs.
Initially, IRAK-M expression was predominantly characterized
in monocytes/macrophages16,20,21. Recently it has been shown
that during respiratory infections, IRAK-M is expressed and
induced, not only in alveolar macrophages, but also in respiratory
epithelial cells22,49,50. In the present study, we found that GCs
synergize with NTHi to induce IRAK-M expression in both
respiratory epithelial cells and alveolar macrophages in vitro and
in vivo. Importantly, GCs are unable to suppress the NTHi-
induced upregulation of proinﬂammatory mediators in IRAK-M-
depleted lung epithelial cells as well as IRAK-M-deﬁcient alveolar
macrophages. Our ﬁndings are in line with previous studies
demonstrating the expression of IRAK-M in non-myeloid cells
including epithelial cells. Thus, it is likely that IRAK-M expressed
in both respiratory epithelial cells and macrophages are involved
in mediating the ability of GCs to suppress inﬂammation induced
by the respiratory bacterial pathogen, NTHi. It should be noted
that our study did not exclude the involvement of other cell types.
Future studies using conditional knockout mice with tissue-/cell
type-speciﬁc deletion of IRAK-M may help determine the
contribution of cell-speciﬁc induction of IRAK-M expression.
IRAK-M has been shown to act as a critical negative regulator
for inﬂammatory responses. In line with previous ﬁndings in
pneumonia models15–20,51, we observed elevated inﬂammatory
responses in the lung of IRAK-M-deﬁcient mice compared with
WT mice. We found that GCs suppressed the NTHi-induced
inﬂammation and signiﬁcantly improved the survival rate in WT
mice but not in IRAK-M-deﬁcient mice (Fig. 4f). Interestingly,
no statistically signiﬁcant difference in survival rate was found
between DEX-untreated WT and IRAK-M-deﬁcient mice
although IRAK-M-deﬁcient mice show a trend of better
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Figure 7 | A schematic representation of suppression of inﬂammation
by GCs via the upregulation of IRAK-M expression.
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survival. Our ﬁnding is consistent with a recent study showing a
reduced lethality in IRAK-M-deﬁcient mice after infection with
S. pneumonia via the airway20. Given that the markers of
inﬂammation are indeed elevated in IRAK-M-deﬁcient mice, it is
unclear why IRAK-M-deﬁcient mice did not show an increased
mortality. Although the current study does not provide a clear
explanation for this apparent anomaly, our preliminary ﬁnding
on the negative role of IRAK-M in bacteria-induced mucus
production may provide possible explanations for this difference.
Recently, there is an increasing evidence suggesting that the host
has the ability to reduce the tissue damage caused directly by both
pathogens and immunopathology through the enhancement of
tolerance mechanisms, thus improving host survival52. IRAK-M
may act as a negative regulator for NTHi-induced host tolerance.
Indeed, our preliminary studies revealed that IRAK-M is also a
negative regulator for bacteria-induced mucus production, an
important mucosal defense mechanism for protecting the host
from inﬂammation- and pathogen-induced tissue damage. Thus,
IRAK-M-deﬁciency results in, not only overactive inﬂammation,
but also overproduced mucus, which are apparently
counteractive. This disparity may explain why IRAK-M-
deﬁcient mice did not show an increased mortality. Future
studies using mice deﬁcient in mucus production may help to
further address this question.
In conclusion, our studies unveil a novel mechanism by which
GCs suppress bacteria-induced innate immune and inﬂammatory
responses by upregulating IRAK-M. Our study provides new
insights into the previously unidentiﬁed role of GCs in
suppressing inﬂammation by targeting the central bottleneck
proteins MyD88 and IRAK1/4. It may also lead to the
development of new therapeutic strategies to control overactive
inﬂammation.
Methods
Reagents and antibodies. DEX, Mifepristone (RU486) and Actinomycin D were
purchased from Sigma-Aldrich. Compound A was purchased from Enzo Life
Science. IKK2 inhibitor IV was purchased from EMD Millipore. Antibodies:
GR (sc-8992), p65 (sc-8008, sc-372, sc-109), IRAK-M (sc-100389), a-Tubulin
(sc-69969), b-actin (sc-8432), F4/80 (sc-26642), E-cadherin (sc-31020), Donkey
anti-rabbit IgG-FITC (sc-2090) and bovine anti-goat IgG-TR (sc-2786) were
purchased from Santa Cruz Biotechnology, IRAK-M (#2355) from ProSci,
anti-rabbit HRP-linked antibody (#7074) and anti-mouse HRP-linked antibody
(#7076) were from Cell Signaling. siRNAs; GR (cat# L-003424-00-0005,
ON-TARGET plus Human NR3C1 (2908)-SMARTpool, p65 (cat# L-003533-00-
0005, ON-TARGET plus Human RELA (5970) - SMARTpool) and control siRNA
(cat# D-001810-10-05) were from Thermo Scientiﬁc Dharmacon, IRAK-M (IRAK3
(ID 11213) cat# SR307690 and control siRNA (cat# SR30004) were from OriGene.
Mice and animal experiments. Irak-m / mice have been described pre-
viously16, and age-matched (8–9 weeks old) male C57BL/6 J mice were used as
WT controls. For investigation of the NTHi-induced inﬂammation in mice,
anaesthetized mice were intratracheally inoculated with NTHi at a concentration
from 1 107 to 5 108 c.f.u. per mouse and saline was inoculated as control. The
inoculated mice were then killed after NTHi inoculation. For PMN analysis, BAL
ﬂuid was collected by cannulating the trachea with sterilized PBS in mice followed
by staining with Diff-Quik staining system (modiﬁed Giemsa staining). For
isolation of macrophages, we collected BAL ﬂuid with 3ml sterilized PBS.
After centrifuge the BAL ﬂuid, macrophages were puriﬁed by percoll gradient
preparation (Amersham Pharmacia Inc.). For inhibition study, mice were
pretreated with DEX (1mg kg 1) intraperitoneally 2 h before NTHi inoculation.
All animal experiments were approved by the Institutional Animal Care and
Use Committee (IACUC) at Georgia State University.
Histology and immunostaining. For histological analysis, formalin-ﬁxed parafﬁn-
embedded lung tissues were sectioned (4 mm) and then stained with haematoxylin
and eosin to visualize inﬂammatory responses and pathological changes in the
lung. The stained sections were then imaged and recorded under light systems
(AxioVert 40 CFL, AxioCam MRC, and AxioVision LE Image system, Carl Zeiss).
The detection of IRAK-M protein was performed using rabbit anti-IRAK-M
(ProSci, 2 mgml 1 for Immunohistochemistry, 10 mgml 1 for Immuno-
ﬂuorescence) and Donkey anti-rabbit-FITC (Santa Cruz Biotechnology,
5 mgml 1) in the parafﬁn section of mouse lung tissue. Blocking IRAK-M peptide
(ProSci, cat# 2355 P, 25 mgml 1) was used for the negative control experiments.
Epithelial cells and macrophages were recognized by antibodies of anti-E-cadherin
(Santa Cruz Biotechnology, 10 mgml 1) and anti-F4/80 (Santa Cruz Biotechnol-
ogy, 10mgml 1), respectively and followed by bovine anti-goat TR (Santa Cruz
Biotechnology, 8 mgml 1) incubation. Inﬂammation score in haematoxylin and
eosin staining (Grade; 0 to 3) and IRAK-M protein expression intensity score in
immunostaining (Grade; 0 to 4) were validated in a blinded fashion53–56.
Bacterial culture. NTHi strain 12 (also known as R2846) used in this study was a
clinically isolated strain that was kindly provided by H. Faden (Children’s Hospital
of Buffalo, State University of New York, Buffalo, NY)57. NTHi were grown on
chocolate agar plate at 37 C in an atmosphere of 5% CO2 overnight and inoculated
in brain heart infusion broth supplemented with 3.5 mgml 1 NAD and
haemoglobin (BD Biosciences). After overnight incubation, bacteria were
subcultured into fresh brain heart infusion and the log phase NTHi, monitored by
measurement of optical density (OD600) value, was washed and suspended in
DMEM for in vitro cell experiments and in isotonic saline for in vivo animal
experiments.
Cell culture. All media described below were supplemented with 10% fetal bovine
serum (Sigma-Aldrich). Human airway epithelial A549 cells were maintained in
F-12 K media (Gibco), BEAS-2B cells in RPMI 1640 media (Gibco). BEAS-2B cells
stably expressing human IRAK-M were obtained by plasmid transfection following
geneticin selection (300 mgml 1). Human primary bronchial epithelial (Lonza)
cells were maintained in BEGM (bronchial epithelial growth media) supplemented
with BEGM SingleQuots. Human peripheral blood CD14þ monocytes (Lonza)
were cultured in RPMI 1640 media (Gibco) containing 1mM pyruvate and
GM-CSF (50 ngml 1; R&D systems). MEF cells were obtained from E13 embryos
and maintained in DMEM (Corning Cellgro). p65 / MEFs reconstituted
with p65 WT were cultured in DMEM (Corning Cellgro) containing puromycin
(1.5 mgml 1). All cells were cultured in a humidiﬁed atmosphere of 5% CO2
at 37 C.
Real-time quantitative RT–PCR analysis. Total RNA was isolated with TRIzol
reagent (Life Technologies) by following the manufacturer’s instruction. The
reverse transcription reaction was performed by using 1 mg of RNA in 25ml of
reaction buffer of TaqMan reverse transcription reagents (Applied Biosystems) and
run under the following protocol: 25 C for 10min, 42 C for 1 h and 95 C for
5min (refs 29,58–60). PCR was performed by using Fast SYBR Green Master Mix
(Life Technologies). In brief, the reactions were performed in triplicate containing
2 Universal Master Mix, 1 ml of template cDNA, 400 nM primers in a ﬁnal
volume of 12.5 ml and they were analysed in a 96-well optical reaction plate
(Applied Biosystems). Reactions were ampliﬁed under the following protocol:
95 C for 20 s followed by 40 cycle of 95 C for 3 s and 60 C for 30 s and quantiﬁed
by using StepOnePlus Real-Time PCR System and the manufacturer’s
corresponding software (StepOnePlus Software v2.3; Applied Biosystems). The
relative quantities of mRNAs were obtained by using the comparative Ct method
and were normalized using human cyclophilin or mouse glyceraldehydes-3-
phosphate dehydrogenase as an endogenous control. The primers are described
in Supplementary Table 1.
Plasmids and transfections. The expression plasmid of a constitutively active
form of IKKb (IKKb-CA, S177E/S181E) was a gift from Dr Anjana Rao
(Addgene plasmid # 11105) (ref. 61). The expression plasmid of p65 was cloned
and the insert was transferred to pcDNA3.1 vector (Life Technologies) with
BamHI and HindIII sites after we ampliﬁed the insert with primers shown in
Supplementary Table 2. The luciferase reporter construct of NF-kB contains three
copies of the NF-kB site from the IL-2 receptor (a) promoter by using the
following oligonucleotides: 50-TCGAGACGGCAGGGGAATCTCCCTCTCCG-30
and 30-CTGCCGTCCCCTTAGAGGGAGAGGCAGCT-50 (refs 27,62). Transient
transfections were carried out using TransIT-LT1 reagent (Mirus) or
Lipofectamine 2000 (Life Technologies) for plasmid DNA, DharmaFECT4
(Thermo Scientiﬁc) for siRNA following the manufacturer’s instruction. For
cloning of human IRAK-M, we used pDONR223-IRAK3 as a template, which was
a gift from Drs William Hahn and David Root (Addgene plasmid # 23627)
(ref. 63). The insert was then transferred to pcDNA3.1 vector (Life Technologies)
with XhoI and BamHI site after we ampliﬁed the insert with primers shown in
Supplementary Table 2. For cloning of IRAK-M promoter, we used BAC clone
RP11-937C6 (BACPAC Resources Center, Children’s Hospital Oakland Research
Institute) as a template. PCR was performed using primers shown in
Supplementary Table 2. PCR products were transferred into pGL3 basic vector
(Promega) with MluI and XhoI site. The sequences were veriﬁed from at least three
clones. The GRE and NF-kB mutants of IRAK-M promoter were constructed by
using the QuikChange II site-directed mutagenesis kit (Agilent Technologies) with
primers shown in Supplementary Table 2.
Western blot analysis. Western blots were performed using whole-cell extracts in
protein lysis buffer (20mM Tris-HCl (pH 7.4), 50mM NaCl, 50mM Na4P2O7,
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30mM NaF, 5 mM ZnCl2, 2mM Iodoacetic acid, 1% Triton-X) with freshly added
1mM sodium orthovanadate and protease inhibitor cocktail (Sigma-Aldrich),
separated on 8% SDS–polyacrylamide gel electrophoresis gels and transferred to
polyvinylidene diﬂuoride membranes. The membrane was blocked with 5% non-fat
dry milk in Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T). The
membrane was then incubated in a 1:2,000 dilution of a primary antibody in 5%
bovine serum albumin–TBS-T at room temperature for 1 h or at 4 C for 16 h.
After washing three times with TBS-T, the membrane was incubated with 1:10,000
dilution of the corresponding secondary antibody in 2.5% non-fat dry milk–TBS-T
at room temperature for 2 h. Respective proteins were developed by using
Amersham ECL Prime Regent (GE Healthcare Biosciences) and image were
obtained by ChemiDoc XRSþ System. Images have been cropped for presentation.
Full-size images are presented in Supplementary Figs 7–9.
Chromatin immunoprecipitation. ChIP assay was performed with minor mod-
iﬁcations of the previous study42,64. The cells were crosslinked by incubation with
1% formaldehyde at room temperature for 10min, followed by incubation with
0.125M glycine for 5min. Cells were washed twice with ice-cold PBS and lysed
with cell lysis buffer (50mM HEPES (pH7.4), 1mM EDTA, 85mM KCl, 10%
glycerol, 0.5% NP40, supplemented with protease inhibitor cocktail). Nuclei was
collected by centrifugation at 850g for 5min and suspended in Nuclei lysis buffer
(50mM Tris-HCl (pH 8.0), 2mM EDTA, 150mM NaCl, 5% glycerol, 1% Triton-
X-100, 0.1% SDS, supplemented with protease inhibitor cocktail). The chromatin
was sheared by sonication (Branson digital sonicator) to an average size 500 bp and
precleared with Protein G PLUS-Agarose (Santa Cruz Biotechnology) or
Dynabeads protein G (Life Technologies). The precleared chromatin was incubated
with 5 mg of primary antibodies overnight at 4 C, followed by incubation with
Protein G PLUS-Agarose or Dynabeads protein G for 2 h. The immunoprecipitates
were washed two times with ChIP wash buffer I (20mM Tris-HCl (pH 8.0),
150mM NaCl, 1% Triton-X-100, 0.1% SDS, 2mM EDTA), two times with ChIP
wash buffer II (20mM Tris-HCl (pH 8.0), 500mM NaCl, 1% Triton-X-100, 0.1%
SDS, 2mM EDTA), one time with ChIP wash buffer III (20m Tris-HCl (pH 8.0),
150mM NaCl, 500mM LiCl, 1% NP40, 1% deoxycholate, 1mM EDTA) and two
times with TE buffer (10mM Tris-HCl (pH 8.0), 1mM EDTA). The precipitated
chromatin complexes were eluted in elution buffer (1% SDS, 0.1M NaHCO3) at
room temperature for 30min with vortex every 5min. After reverse crosslink at
65 C for 18 h and protein digestion with Proteinase K (Thermo Scientiﬁc) at 55 C
for 3 h, DNA was isolated using MiniElute PCR puriﬁcation kit (Quiagen) with
30ml elution with UltraPure DNAase/RNAase-Free Distilled Water (Life
Technologies). PCR was performed with primers shown in Supplementary Table 2.
Re-ChIP. Re-ChIP assay was performed as described previously34. In brief,
crosslinking was performed using 2mM disuccinimidyl glutarate (Thermo
Scientiﬁc) for 45min followed by 1% formaldehyde for 10min at room
temperature. After the ﬁrst IP, immune complexes were eluted in Re-ChIP elution
buffer (10mM Tris-HCl (pH 8.0), 2mM EDTA, 2% SDS, 15mM DTT) including
protease inhibitor cocktail at room temperature for 30min. The elution was diluted
20 times with ChIP dilution buffer (16.7mM Tris-HCl (pH 8.0), 167mM NaCl,
1.2mM EDTA, 1.1% Triton-X) supplemented with protease inhibitor cocktail,
100mgml 1 bovine serum albumin , 100mgml 1 salmon sperm DNA, followed
by second IP. The second IP samples were washed, eluted and puriﬁed as described
above ChIP procedure. PCR was performed with 1 ml puriﬁed DNA by using
PrimeSTAR Max DNA polymerase (Takara) with primers IRAK-M  300 bp
forward and IRAK-M 0 bp reverse shown in Supplementary Table 2.
Statistical analysis. Data are shown as mean±s.d. Statistical analysis was
assessed by t-test. Po0.05 was considered statistically signiﬁcant.
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